A5090179241- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Renal Transplantation Outcomes and Treatments
- Algal biology and biofuel production
- T-cell and B-cell Immunology
- Photosynthetic Processes and Mechanisms
- Retinoids in leukemia and cellular processes
- HER2/EGFR in Cancer Research
- Mycobacterium research and diagnosis
- Biocrusts and Microbial Ecology
- Pneumocystis jirovecii pneumonia detection and treatment
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Virus-based gene therapy research
- Viral-associated cancers and disorders
AdventHealth Orlando
2017-2024
Florida Hospital Cancer Institute
2015-2022
Sarah Cannon
2022
Florida Hospital Medical Group
2017-2021
Taichung Veterans General Hospital
2019
University of Utah
2019
Mayo Clinic
2019
The University of Texas MD Anderson Cancer Center
2000-2008
University of Rochester Medical Center
2005
University of Rochester
2004
Abstract Allogeneic hematopoietic cell transplant is a potential curative therapy for acute lymphoblastic leukemia (ALL). Delineating the graft-versus-leukemia (GVL) effect as function of graft-versus-host disease (GVHD) offers to improve survival. We examined 5215 recipients with ALL reported Center International Blood and Marrow Transplant Research registry. Overall survival (OS) was compared according presence severity GVHD evaluated in 3 cohorts: 2593 adults first or second complete...
Thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-SCT) can pose significant problems in management of patients. Eltrombopag is a small-molecule thrombopoietin receptor agonist that has been approved for use immune thrombocytopenic purpura and aplastic anemia; but its allo-SCT limited. Between 2014 2017, we treated 13 patients with eltrombopag poor platelet engraftment without evidence relapse at the time initiation, including 6 primary failure 7 secondary...
Infections in adult patients with hematological malignancies (HM) and stem cell transplant (SCT) recipients are a significant cause of morbidity mortality. A timely diagnosis infections can have major impact on outcomes. Tools that help rule out infectious causes fever decrease antibiotic use, toxicities, hospitalization costs, potentially resistance the long term. We retrospectively evaluated ability cell-free DNA next-generation sequencing (NGS) testing identification pathogenic...
Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine prognostic impact cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated matched sibling donors reported Center for...
Azacitidine (AZA) maintenance following allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) may reduce relapse risk improve survival. Given logistic toxicity-related challenges, identifying subgroups appropriate this approach is an unmet need. Using data from two centers, we retrospectively compared event-free survival (EFS) overall (OS) of AML MDS patients who received AZA (n = 59) with historic controls 90). Controls were...
Unlike unrelated donor registries, transplant centers lack uniform approaches to related assessment and deferral. To test whether donors are at increased risk for donation-related toxicities, we conducted a prospective observational trial of 11,942 aged 18–60 years. Bone marrow (BM) was collected 37 78 National Marrow Donor Program centers, peripheral blood stem cells (PBSC) were 42 87 in North America. Possible presence medical comorbidities verified prior donation, standardized pain...
The development of reduced-intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers older related donors (RDs) peripheral blood stem cells (PBSCs). effects age on donation efficacy, toxicity, and long-term recovery RDs are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms, 1211 PBSC aged 18 to 79 enrolled the Related Donor Safety Study. > 60 had a lower median CD34+ level before apheresis...
We analyzed access barriers to anti-CD19+ chimeric antigen receptor T-cells (CART) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. 357 intended recipients of FDA-approved CART were identified in the study period (2018 2022). Results showed that median age at referral was 61 years, year 2018 (4%), 2019 (14%), 2020 (18%), 2021 (26%), 2022 (38%). Diagnoses diffuse large B-cell (69%), follicular (13%), follicular/large (7%), mantle or other...
Abstract Progressive multifocal leukoencephalopathy ( PML ) is a rare, yet typically fatal complication of allogeneic stem cell transplantation. It caused by reactivation the John Cunningham JC virus in an immunocompromised host. This report describes unfortunate case recipient transplant for acute myelogenous leukemia. The was undetectable patient's cerebrospinal fluid polymerase chain reaction PCR ); however, positive diagnosis made after brain biopsy. and other published cases demonstrate...
Although donation of bone marrow (BM) or peripheral blood stem cells (PBSCs) from children to family members undergoing allogeneic transplantation are well-established procedures, studies detailing levels pain, symptoms, and long-term recovery lacking. To address this lack, we prospectively enrolled 294 donors age <18 years at 25 pediatric centers in North America, assessing them predonation, peridonation, 1 month, 6 months, year postdonation. We noted that 71% reported pain 59% other...
The programmed death 1 (PD-1) pathway is a negative regulator of T-cell–mediated immunity. Tumour cells expressing PD1 receptor can engage ligands on immune effector and evade the response. Nivolumab member new class immunotherapies, so called “checkpoint” inhibitors, with tremendous activity in solid tumours as well Hodgkins lymphoma.1
Acute graft-versus-host disease (aGvHD) is a life-threatening complication typically occurring within 100 days after allogeneic hematopoietic cell transplantation (allo-HCT). This hypothesis-generating, phase II, prospective, open-label, randomized study (clinicaltrials gov. Identifier: NCT03339297) compared defibrotide added to standard-of-care (SOC) GvHD prophylaxis (defibrotide arm) versus SOC alone (SOC prevent aGvHD post-transplant. estimated incidences of and was not statistically...
Biochemical responses to cold and osmotic stresses overlap because each decreases the availability of free water. Since RNA-binding proteins are known accumulate following stress play key roles in regulating transcription termination, effect on expression was examined. The transcript levels four genes encoding (rbpA, rbpB, rbpC rbpD) were monitored Anabaena sp. PCC 7120 cultures supplemented with ammonium ions or growing under nitrogen-fixing conditions. Steady-state all increased...
Using differential display, we identified the Anabaena sp. PCC 7120 ribulose 1,5-bisphosphate carboxylase transcriptional regulator (rbcR1) gene, a member of LysR family positive transcription factors. The rbcR1 transcript and its putative target gene carboxylase/oxygenase (rbcL/S) were repressed by cold (20°C) osmotic (sucrose salt) stress. Cold stress also induced transient downregulation ntcA regulator. Expression however, returned to normal levels 2 h after initiation increased...
Background The inhibition of programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) signaling pathway has been shown to be an effective targeted therapy in fighting both solid organ cancers and hematological malignancies. PD-L1 expression also serves as a prognostic marker various cancers. However, the its significance multiple myeloma remains largely unknown. Methods Immunohistochemistry staining was performed bone marrow biopsy samples (total 85 samples) 32 patients...
Click to increase image sizeClick decrease sizeKeywordsTransplantationtumor immunityvaccinationgraft vs. host diseaseleukemiagraft leukemiaT-cell depletion